Pluristem Therapeutics Company Profile (NASDAQ:PSTI)

About Pluristem Therapeutics

Pluristem Therapeutics logoPluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PSTI
  • CUSIP:
Key Metrics:
  • Previous Close: $1.13
  • 50 Day Moving Average: $1.23
  • 200 Day Moving Average: $1.48
  • 52-Week Range: $1.04 - $1.85
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.11
  • P/E Growth: 0.00
  • Market Cap: $107.59M
  • Outstanding Shares: 96,065,000
  • Beta: 0.12
Profitability:
  • Return on Equity: -75.68%
  • Return on Assets: -62.58%
Debt:
  • Current Ratio: 4.27%
  • Quick Ratio: 4.27%
Additional Links:
Companies Related to Pluristem Therapeutics:

Analyst Ratings

Consensus Ratings for Pluristem Therapeutics (NASDAQ:PSTI) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $4.33 (286.90% upside)

Analysts' Ratings History for Pluristem Therapeutics (NASDAQ:PSTI)
Show:
DateFirmActionRatingPrice TargetDetails
2/13/2017Maxim GroupDowngradeBuy -> HoldView Rating Details
2/11/2017HC WainwrightSet Price TargetBuy$4.00View Rating Details
1/10/2017FBR & CoReiterated RatingBuyView Rating Details
8/14/2015MLV & Co.Reiterated RatingBuy$6.00View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Pluristem Therapeutics (NASDAQ:PSTI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/13/2017        
11/24/2014($0.13)($0.09)ViewN/AView Earnings Details
10/6/2014($0.13)($0.09)ViewN/AView Earnings Details
9/11/2014($0.15)($0.09)ViewN/AView Earnings Details
5/22/2014($0.14)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pluristem Therapeutics (NASDAQ:PSTI)
Current Year EPS Consensus Estimate: $-0.32 EPS
Next Year EPS Consensus Estimate: $-0.36 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.10)($0.10)($0.10)
Q2 20161($0.10)($0.10)($0.10)
Q4 20161($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Pluristem Therapeutics (NASDAQ:PSTI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Pluristem Therapeutics (NASDAQ:PSTI)
Insider Ownership Percentage: 8.17%
Institutional Ownership Percentage: 3.05%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/22/2016Zami AbermanCEOBuy5,000$1.33$6,650.00View SEC Filing  
2/18/2016Yaky YanayCFOBuy5,000$1.20$6,000.00View SEC Filing  
2/16/2016Yaky YanayCFOBuy15,000$0.95$14,250.00View SEC Filing  
2/15/2016Doron ShorrerDirectorBuy12,346$0.81$10,000.26View SEC Filing  
2/12/2016Yaky YanayCFOBuy5,000$0.83$4,150.00View SEC Filing  
2/11/2016Israel Ben-YoramDirectorBuy10,000$0.79$7,900.00View SEC Filing  
2/11/2016Zami AbermanCEOBuy31,000$0.80$24,800.00View SEC Filing  
11/16/2015Yaky YanayCFOBuy10,000$1.52$15,200.00View SEC Filing  
11/16/2015Zami AbermanCEOBuy9,900$1.49$14,751.00View SEC Filing  
9/21/2015Israel Ben-YoramDirectorSell30,000$2.10$63,000.00View SEC Filing  
9/21/2015Yaky YanayCFOBuy10,000$2.11$21,100.00View SEC Filing  
9/21/2015Zami AbermanCEOBuy25,500$2.11$53,805.00View SEC Filing  
9/16/2015Yaky YanayCFOBuy10,000$2.12$21,200.00View SEC Filing  
9/15/2015Zami AbermanCEOBuy25,000$2.11$52,750.00View SEC Filing  
11/11/2014Yaky YanayCOOBuy11,000$2.62$28,820.00View SEC Filing  
11/11/2014Zami AbermanCEOBuy13,000$2.64$34,320.00View SEC Filing  
9/22/2014Yaky YanayCOOBuy11,000$2.95$32,450.00View SEC Filing  
9/22/2014Zami AbermanCEOBuy5,000$2.92$14,600.00View SEC Filing  
9/21/2014Zami AbermanCEOBuy5,000$2.96$14,800.00View SEC Filing  
9/17/2014Israel Ben-YoramDirectorBuy5,000$2.82$14,100.00View SEC Filing  
9/16/2014Boaz Gur-LavieCFOBuy3,478$2.84$9,877.52View SEC Filing  
9/16/2014Yaky YanayCOOBuy10,000$2.85$28,500.00View SEC Filing  
9/16/2014Zami AbermanCEOBuy15,000$2.80$42,000.00View SEC Filing  
6/18/2014Mark GermainDirectorSell43,215$3.12$134,830.80View SEC Filing  
1/17/2014Israel Ben-YoramDirectorSell35,625$4.51$160,668.75View SEC Filing  
1/13/2014Israel Ben-YoramDirectorSell26,453$4.29$113,483.37View SEC Filing  
1/13/2014Yaky YanayCFOSell69,850$4.29$299,656.50View SEC Filing  
1/9/2014Yaky YanayCFOSell30,150$4.25$128,137.50View SEC Filing  
1/8/2014Israel Ben-YoramDirectorSell44,797$4.12$184,563.64View SEC Filing  
11/11/2013Nachum RosmanDirectorSell67,244$3.27$219,887.88View SEC Filing  
9/12/2013Israel Ben-YoramDirectorSell52,000$3.07$159,640.00View SEC Filing  
5/20/2013Israel Ben-YoramDirectorSell45,429$3.03$137,649.87View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Pluristem Therapeutics (NASDAQ:PSTI)
DateHeadline
News IconAnalyst Recommendations on These Shares: Pluristem ... - Davidson Register (NASDAQ:PSTI)
davidsonregister.com - February 23 at 8:47 AM
capitalcube.com logoPluristem Therapeutics, Inc. :PSTI-US: Earnings Analysis: Q2, 2017 By the Numbers (NASDAQ:PSTI)
www.capitalcube.com - February 22 at 7:31 PM
investornewswire.com logoStrong Sell Recommendations Of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) At 0 - Investor Newswire (NASDAQ:PSTI)
www.investornewswire.com - February 20 at 6:35 PM
finance.yahoo.com logoPLURISTEM THERAPEUTICS INC Financials (NASDAQ:PSTI)
finance.yahoo.com - February 14 at 11:55 PM
finance.yahoo.com logoPluristem Therapeutics downgraded by Maxim Group (NASDAQ:PSTI)
finance.yahoo.com - February 14 at 3:16 AM
us.rd.yahoo.com logoPluristem Reports Second Quarter Fiscal 2017 Highlights & Provides Calendar 2017 Outlook (NASDAQ:PSTI)
us.rd.yahoo.com - February 13 at 9:04 AM
sg.finance.yahoo.com logoPluristem reports 2Q loss (NASDAQ:PSTI)
sg.finance.yahoo.com - February 9 at 10:05 PM
News IconEquity Scope: Looking at Shares of Pluristem Therapeutics Inc. (PSTI) - Rives Journal (NASDAQ:PSTI)
rivesjournal.com - February 8 at 9:26 PM
News IconCompany Watch: Viewing Levels for Pluristem Therapeutics Inc. (PSTI) - Piedmont Register (NASDAQ:PSTI)
piedmontregister.com - February 8 at 9:26 PM
biz.yahoo.com logoPLURISTEM THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:PSTI)
biz.yahoo.com - February 8 at 9:25 PM
News IconGrowth Story Unfolding for Pluristem Therapeutics Inc. (NASDAQ:PSTI) - Prospect Journal (NASDAQ:PSTI)
prospectjournal.com - January 30 at 8:01 PM
News IconCan This Stock Gain Any Traction: Pluristem Therapeutics Inc. (NASDAQ:PSTI) - Prospect Journal (NASDAQ:PSTI)
prospectjournal.com - January 30 at 8:01 PM
News IconRSI Update on Shares of Pluristem Therapeutics Inc. (PSTI) - Sherwood Daily (NASDAQ:PSTI)
sherwooddaily.com - January 30 at 8:01 PM
tmcnet.com logoPluristem Announces Closing of Bought Offering and Underwriter's Exercise in Full of Over-Allotment Option (NASDAQ:PSTI)
www.tmcnet.com - January 26 at 2:19 AM
finance.yahoo.com logoPluristem Announces Closing of Bought Offering and Underwriter’s Exercise in Full of Over-Allotment Option (NASDAQ:PSTI)
finance.yahoo.com - January 26 at 2:19 AM
News IconEquity Rundown: RSI and CCI Check on Pluristem Therapeutics Inc. (PSTI) - Sherwood Daily (NASDAQ:PSTI)
sherwooddaily.com - January 25 at 1:09 AM
News IconUnusual Activity Unfolding Mid-Session For Pluristem Therapeutics Inc. (NASDAQ:PSTI) - Aiken Advocate (NASDAQ:PSTI)
aikenadvocate.com - January 25 at 1:08 AM
News IconNext Weeks Broker Price Targets For Pluristem Therapeutics, Inc. (PSTI) (NASDAQ:PSTI)
prensariotiretail.com - January 24 at 8:08 PM
News IconPriming The Pump: Stock Volatility Spotted in Pluristem Therapeutics Inc. (NASDAQ:PSTI) - Wall Street Beacon (NASDAQ:PSTI)
wsbeacon.com - January 24 at 8:27 AM
4-traders.com logoPluristem Therapeutics : Increases Previously Announced Bought Deal Offering of Common Stock and Warrants to $15,000,000 (NASDAQ:PSTI)
www.4-traders.com - January 22 at 7:07 PM
News IconThe Pluristem Therapeutics' (PSTI) Outperform Rating Reaffirmed at FBR & Co (NASDAQ:PSTI)
perspectivabetica.com - January 22 at 7:07 PM
News IconShares Relinquishing Value Pre-Market Open: Pluristem Therapeutics Inc. (NASDAQ:PSTI) - Aiken Advocate (NASDAQ:PSTI)
aikenadvocate.com - January 21 at 1:17 AM
News IconAmplified Volatility Spotted in Shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) - Wall Street Beacon (NASDAQ:PSTI)
wsbeacon.com - January 21 at 1:17 AM
streetinsider.com logoPluristem Therapeutics (PSTI) Increases Bought Deal Offering of Common Stock and Warrants to $15M - StreetInsider.com (NASDAQ:PSTI)
www.streetinsider.com - January 21 at 1:17 AM
streetinsider.com logoPluristem Therapeutics (PSTI) Increases Bought Deal Offering of Common Stock and Warrants to $15M (NASDAQ:PSTI)
www.streetinsider.com - January 20 at 8:15 PM
us.rd.yahoo.com logoPluristem Increases Previously Announced Bought Deal Offering of Common Stock and Warrants to $15,000,000 (NASDAQ:PSTI)
us.rd.yahoo.com - January 20 at 8:15 PM
biz.yahoo.com logoPLURISTEM THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E (NASDAQ:PSTI)
biz.yahoo.com - January 20 at 8:15 PM
4-traders.com logoPluristem Therapeutics : Announces Bought Deal Offering (NASDAQ:PSTI)
www.4-traders.com - January 20 at 6:20 AM
us.rd.yahoo.com logoPluristem Announces Bought Deal Offering (NASDAQ:PSTI)
us.rd.yahoo.com - January 20 at 6:20 AM
us.rd.yahoo.com logo4:55 pm Pluristem Therapeutics announces $10 mln bought deal offering (NASDAQ:PSTI)
us.rd.yahoo.com - January 20 at 6:20 AM
News IconCan This Stock Make a Ripple in the Market: Pluristem Therapeutics Inc. (NASDAQ:PSTI) - Prospect Journal (NASDAQ:PSTI)
prospectjournal.com - January 19 at 1:01 AM
News IconWill The Needle Move For Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:PSTI)
wsbeacon.com - January 18 at 8:26 AM
News IconStock in the Limelight: Pluristem Therapeutics Inc. (NASDAQ:PSTI) - Prospect Journal (NASDAQ:PSTI)
prospectjournal.com - January 18 at 8:26 AM
News IconNews Impact Score Of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Set At 0 - Stock Observer (NASDAQ:PSTI)
www.thestockobserver.com - January 18 at 8:26 AM
streetinsider.com logoPluristem Therapeutics (PSTI) Reports Clearance in Germany to Initiate Phase III Trial of PLX-PAD Cells in CLI - StreetInsider.com (NASDAQ:PSTI)
www.streetinsider.com - January 18 at 8:26 AM
4-traders.com logoPLURISTEM THERAPEUTICS INC : Other Events (form 8-K) (NASDAQ:PSTI)
www.4-traders.com - January 17 at 7:45 PM
streetinsider.com logoPluristem Therapeutics (PSTI) Reports Clearance in Germany to Initiate Phase III Trial of PLX-PAD Cells in CLI (NASDAQ:PSTI)
www.streetinsider.com - January 17 at 7:45 PM
finance.yahoo.com logoFlood of News Presents Buying Opportunity (NASDAQ:PSTI)
finance.yahoo.com - January 17 at 7:45 PM
News IconPluristem Receives Clearance from Germany to Initiate its [..] (NASDAQ:PSTI)
www.pr-inside.com - January 17 at 10:54 AM
finance.yahoo.com logoPluristem Receives Clearance from Germany to Initiate its Multinational Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing Approval (NASDAQ:PSTI)
finance.yahoo.com - January 17 at 10:54 AM
finance.yahoo.com logo6:05 am Pluristem Therapeutics receives clearance in Germany to initiate Phase III trial of PLX-PAD cells to treat Critical Limb Ischemia (NASDAQ:PSTI)
finance.yahoo.com - January 17 at 10:54 AM
News IconHeady Investors are Taking a Look at Pluristem Therapeutics, Inc. (NASDAQ:PSTI) - Prospect Journal (NASDAQ:PSTI)
prospectjournal.com - January 13 at 1:02 AM
streetinsider.com logoPluristem Therapeutics (PSTI) Completes Phase II PLX-PAD Patient Enrollment (NASDAQ:PSTI)
www.streetinsider.com - January 12 at 8:00 PM
capitalcube.com logoPluristem Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PSTI-US : January 12, 2017 (NASDAQ:PSTI)
www.capitalcube.com - January 12 at 8:00 PM
finance.yahoo.com logoPluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication (NASDAQ:PSTI)
finance.yahoo.com - January 12 at 8:00 PM
marketexclusive.com logoPluristem Therapeutics Inc. (NASDSAQ:PSTI) To Begin CLI Phase III Trial Enrolling Only 250 Patients, With FDA Blessing - Market Exclusive (NASDAQ:PSTI)
marketexclusive.com - January 12 at 1:02 AM
News IconPluristem's Phase III Study Of PLX-PAD Cells For The Treatment Of Critical Limb Ischemia Cleared By U.S. FDA (NASDAQ:PSTI)
www.clinicalleader.com - January 11 at 8:02 PM
biz.yahoo.com logoPLURISTEM THERAPEUTICS INC Files SEC form 8-K, Other Events (NASDAQ:PSTI)
us.rd.yahoo.com - January 11 at 8:01 PM
News IconPluristem Therapeutics Inc. (PSTI) To Begin CLI Phase III Trial Enrolling Only 250 Patients, With FDA Blessing (NASDAQ:PSTI)
feedproxy.google.com - January 11 at 3:22 PM
News IconPluristem Therapeutics Jumps as the FDA Clears Critical Limb Ischemia Trial (NASDAQ:PSTI)
www.biospace.com - January 11 at 1:36 AM

Social

What is Pluristem Therapeutics' stock symbol?

Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."

Where is Pluristem Therapeutics' stock going? Where will Pluristem Therapeutics' stock price be in 2017?

3 brokers have issued twelve-month price objectives for Pluristem Therapeutics' stock. Their predictions range from $3.00 to $6.00. On average, they anticipate Pluristem Therapeutics' share price to reach $4.33 in the next twelve months.

When will Pluristem Therapeutics announce their earnings?

Pluristem Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 13th 2017.

What are analysts saying about Pluristem Therapeutics stock?

Here are some recent quotes from research analysts about Pluristem Therapeutics stock:

  • According to Zacks Investment Research, "PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. " (2/15/2017)

  • Maxim Group analysts commented, "A more comprehensive black box warning added to fluoroquinolone labels. Yesterday, the FDA issued a Drug Safety Communication that it had approved an updated safety label for all fluoroquinolone antibacterial drugs to include an updated Boxed Warning about the risk of disabling and potentially irreversible serious reactions that can occur together. This action by the FDA is a follow-up to a May 12, 2016, drug safety communication requiring the drug labels and Medication Guides for all fluoroquinolones to include a revised Boxed Warnings, which in turn is the result of an Advisory Committee meeting held last November on the safety of this drug class. What appears to be new here is the addition of a statement advising restricted use of fluoroquinolones for patients who lack alternative treatment options for indications, such as uncomplicated urinary tract infection (uUTIs), acute bacterial exacerbations of chronic bronchitis (ABECB), and acute bacterial sinusitis (ABS)." (7/27/2016)

Who owns Pluristem Therapeutics stock?

Pluristem Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.76%). Company insiders that own Pluristem Therapeutics stock include Doron Shorrer, Israel Ben-Yoram, Yaky Yanay and Zami Aberman.

Who bought Pluristem Therapeutics stock? Who is buying Pluristem Therapeutics stock?

Pluristem Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Pluristem Therapeutics stock in the last two years include Doron Shorrer, Israel Ben-Yoram, Yaky Yanay and Zami Aberman.

How do I buy Pluristem Therapeutics stock?

Shares of Pluristem Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Pluristem Therapeutics stock cost?

One share of Pluristem Therapeutics stock can currently be purchased for approximately $1.12.

Pluristem Therapeutics (NASDAQ:PSTI) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)

Earnings History Chart

Earnings by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)

Dividend History Chart

Dividend Payments by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)

Last Updated on 2/25/2017 by MarketBeat.com Staff